Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
04 Sep 2020
Historique:
entrez: 9 9 2020
pubmed: 10 9 2020
medline: 24 9 2020
Statut: ppublish

Résumé

Complex immune dysregulation in interferon (IFN) and T cell response has been observed in human immunodeficiency virus (HIV-1)-infected patients as well as in coronavirus disease-2019 (COVID-19) patients. However, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/HIV-1 coinfection has been described in only few cases worldwide and no data are available on immunological outcomes in HIV-1-patients infected with SARS-CoV-2. Hence, this study aims to compare type I IFN response and T cell activation levels between a SARS-CoV-2/HIV-1-coinfected female patient and age-matched HIV-1-positive or uninfected women. A 52-year-old woman diagnosed with SARS-CoV-2/HIV-1 coinfection, ten HIV-1-positive women and five age-matched-healthy individuals were enrolled in this study. SARS-CoV-2 infection caused severe pneumonia in the second week of illness in HIV-1-positive patient under protease inhibitors. Chest high-resolution computed tomography images of the SARS-CoV-2/HIV-1-coinfected patient showed bilateral ground-glass opacities. SARS-CoV-2/HIV-1-coinfected female patient under darunavir/cobicistat regimen received a 7-days hydroxychloroquine therapy. Analysis of IFNα/β mRNA levels and CD4 and CD8 T cell (CD38, human leukocyte antigen-DR [HLA-DR], CD38 HLA-DR) frequencies were performed by RT/real-time PCR assays and flow cytometry, respectively. Median relative difference (MRD) was calculated for each immunological variable. For values greater than reference, MRD should be a positive number and for values that are smaller, MRD should be negative. The severe pneumonia observed in SARS-CoV-2/HIV-1-positive patient under protease inhibitors was reversed by a 7-days hydroxychloroquine therapy. At the end of treatment, on day 7, patient reported resolution of fever, normalization of respiratory rate (14 breaths/min), and improved oxygen arterial pressure with a FiO2 of 30%. MRD values for IFNα/β and CD4 and CD8 T cells expressing CD38 and/or HLA-DR found in SARS-CoV-2-/HIV-1-coinfected woman were approximatively equal to 0 when refereed respectively to HIV-1-positive female patients [MRDs IFNα/β: median -0.2545 (range: -0.5/0.1); T cells: median -0.11 (range: -0.8/1.3)] and ≥ 6 when referred to healthy individuals [MRDs IFNα/β: median 28.45 (range: 15/41.9); T cells: median 10 (range 6/22)]. These results indicate that SARS-CoV-2 infection in HIV-1-positive female patient was associated with increased levels of IFNα/β-mRNAs and T cell activation compared to healthy individuals.

Identifiants

pubmed: 32899009
doi: 10.1097/MD.0000000000021803
pii: 00005792-202009040-00021
pmc: PMC7478511
doi:

Substances chimiques

Anti-Retroviral Agents 0
Enzyme Inhibitors 0
RNA, Messenger 0
Hydroxychloroquine 4QWG6N8QKH
Interferons 9008-11-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e21803

Commentaires et corrections

Type : ErratumIn

Références

Health Equity. 2020 Apr 17;4(1):139-141
pubmed: 32368712
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
J Clin Virol. 2020 Jul;128:104450
pubmed: 32464309
Med Microbiol Immunol. 2019 Oct;208(5):679-691
pubmed: 30564919
Lancet HIV. 2020 May;7(5):e314-e316
pubmed: 32304642
Infection. 2020 Oct;48(5):681-686
pubmed: 32394344
J Infect. 2013 Dec;67(6):606-16
pubmed: 24096239
J Med Virol. 2020 Jun;92(6):529-530
pubmed: 32160316
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2
pubmed: 32407669
Immunol Rev. 2013 Jul;254(1):78-101
pubmed: 23772616
J Am Coll Cardiol. 2020 Jun 2;75(21):2746-2748
pubmed: 32330545
Cytokine Growth Factor Rev. 2018 Apr;40:19-31
pubmed: 29576284
Int J Infect Dis. 2020 Jul;96:148-150
pubmed: 32335339
Cytokine. 2019 Aug;120:273-281
pubmed: 30910260
Expert Rev Respir Med. 2016 Apr;10(4):463-472
pubmed: 26918376
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Clin Infect Dis. 2020 Nov 19;71(16):2276-2278
pubmed: 32407467
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
Cell Discov. 2020 May 4;6:31
pubmed: 32377375
J Racial Ethn Health Disparities. 2020 Jun;7(3):398-402
pubmed: 32306369
Biol Sex Differ. 2020 May 1;11(1):23
pubmed: 32357901

Auteurs

Gabriella d'Ettorre (G)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.

Gregorio Recchia (G)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.

Marco Ridolfi (M)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.

Guido Siccardi (G)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.

Claudia Pinacchio (C)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.

Giuseppe Pietro Innocenti (GP)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.

Letizia Santinelli (L)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.

Federica Frasca (F)

Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.

Camilla Bitossi (C)

Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.

Giancarlo Ceccarelli (G)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.

Cristian Borrazzo (C)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.

Guido Antonelli (G)

Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.
Microbiology and Virology Unit, Hospital "Policlinico Umberto I", Sapienza University, Rome, Italy.

Carolina Scagnolari (C)

Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.

Claudio Maria Mastroianni (CM)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH